Hookipa Pharma (NASDAQ:HOOK) Given Neutral Rating at HC Wainwright

Hookipa Pharma (NASDAQ:HOOK)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a report released on Friday,Benzinga reports.

A number of other brokerages also recently issued reports on HOOK. Royal Bank of Canada downgraded Hookipa Pharma from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $48.00 to $2.00 in a research report on Friday, December 20th. JMP Securities lowered their price target on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, November 21st.

Hookipa Pharma Stock Down 1.6 %

Shares of NASDAQ:HOOK opened at $1.86 on Friday. The firm has a fifty day simple moving average of $2.52 and a two-hundred day simple moving average of $4.14. The stock has a market capitalization of $22.42 million, a P/E ratio of -0.50 and a beta of 0.71. Hookipa Pharma has a 52 week low of $1.75 and a 52 week high of $10.50.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in shares of Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after acquiring an additional 83,800 shares during the last quarter. Ikarian Capital LLC bought a new stake in shares of Hookipa Pharma during the third quarter worth $228,000. Finally, Acadian Asset Management LLC boosted its stake in shares of Hookipa Pharma by 12.3% during the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after purchasing an additional 108,844 shares during the period. Institutional investors own 63.88% of the company’s stock.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.